EIF4E2
Eukaryotic translation initiation factor 4E type 2
Also known as: 4EHP, EIF4EL3, IF4e, IF4E2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O60573
- Gene
- EIF4E2
- Ensembl
- ENSG00000135930
- Chromosome
- 2
- Canonical length
- 245 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Mitochondria,Cytosol
OverviewNCBI Gene
Enables RNA 7-methylguanosine cap binding activity; mRNA cap binding activity; and ubiquitin protein ligase binding activity. Involved in negative regulation of translational initiation; negative regulation of type I interferon-mediated signaling pathway; and rescue of stalled ribosome. Acts upstream of with a positive effect on miRNA-mediated gene silencing by inhibition of translation. Acts upstream of or within negative regulation of translation. Located in P-body. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
245 residues, UniProt reviewed canonical sequence.
>O60573|EIF4E2
1 MNNKFDALKD DDSGDHDQNE ENSTQKDGEK EKTERDKNQS SSKRKAVVPG PAEHPLQYNY
61 TFWYSRRTPG RPTSSQSYEQ NIKQIGTFAS VEQFWRFYSH MVRPGDLTGH SDFHLFKEGI
121 KPMWEDDANK NGGKWIIRLR KGLASRCWEN LILAMLGEQF MVGEEICGAV VSVRFQEDII
181 SIWNKTASDQ ATTARIRDTL RRVLNLPPNT IMEYKTHTDS IKMPGRLGPQ RLLFQNLWKP
241 RLNVPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EIF4E2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 145 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 145 nTPM
- liver: 85 nTPM
- rectum: 68 nTPM
- colon: 63 nTPM
- kidney: 58 nTPM
- tongue: 58 nTPM
Single-cell type
- late spermatids: 489 nCPM
- extravillous trophoblasts: 278 nCPM
- myonuclei: 253 nCPM
- esophageal apical cells: 242 nCPM
- syncytiotrophoblasts: 224 nCPM
- esophageal suprabasal cells: 206 nCPM
Immune cell
- basophil: 301 nTPM
- intermediate monocyte: 223 nTPM
- non-classical monocyte: 209 nTPM
- classical monocyte: 209 nTPM
- eosinophil: 197 nTPM
- myeloid DC: 183 nTPM
Brain region
- pons: 35 nTPM
- thalamus: 34 nTPM
- medulla oblongata: 33 nTPM
- hypothalamus: 32 nTPM
- white matter: 32 nTPM
- cerebral cortex: 31 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.5
- gnomAD pLI
- 0.58
- gnomAD missense Z
- 2.33
- DepMap mean gene effect
- -0.27
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- miRNA-mediated gene silencing by inhibition of translation
- negative regulation of translation
- negative regulation of translational initiation
- negative regulation of type I interferon-mediated signaling pathway
- rescue of stalled ribosome
- translational initiation
Molecular functions
- mRNA cap binding
- RNA 7-methylguanosine cap binding
- RNA binding
- RNA cap binding
- translation factor activity, RNA binding
- translation initiation factor activity
- ubiquitin protein ligase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EIF4E2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EIF4E2 as an antibody target. Whether an autoantibody or antibody against EIF4E2 could matter depends on whether native EIF4E2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EIF4E2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label EIF4E2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...